Update On Imam Jamil Al-Amin's Medical Condition

Re: Update on Imam Jamil Al-Amin’s Medical Condition 
Reg. No. 99974-555
Date: September 15, 2014

For two months, Imam Jamil Al-Amin has undergone tests at the Butner FMC as a result of our successful campaign to have him transferred out of the Florence ADX to the federal medical center. 
The campaign was necessary to bring attention to his failing medical health that the Florence ADX continued to ignore.  For those who joined us in advocating on behalf of Imam Jamil, and to those who have sent letters and cards to him, we continue to extend our appreciation.

We are able to report that Imam Jamil has smoldering myeloma, which is an inactive form of multiple myeloma. Individuals with smoldering myeloma generally are monitored without receiving treatment, although there are studies that indicate early intervention with medication could prevent the progression to active multiple myeloma. The physicians at Butner FMC have not recommended that Imam Jamil receive any medication for his smoldering myeloma. They agree that he should be monitored and tested every two to three months to determine if his condition has progressed; then and only then would he receive aggressive treatment if the test results reveal he has active multiple myeloma.

Although Imam Jamil has other medical conditions, which we feel have not been addressed adequately at the Butner FMC, he is “awaiting transfer.” In this regard, we plan to do the following and ask you again to join us in raising our collective voices to prevent another injustice:

•  continue to oppose Jamil Al-Amin’s return to the Florence ADX, and challenge any FBOP’s decision to house him in another federal facility under solitary confinement conditions in his chronic medical state;
•  continue to call for Jamil Al-Amin to be held, pending his appeals, in a state or federal Georgia prison to have access to his team of attorneys;
• and continue to urge close monitoring and exploration of treatment for Jamil Al-Amin’s medical conditions. 

 Please raise these concerns with any of the following: 

 Charles E. Samuels, Jr., Director, Federal Bureau of Prisons, 202-307-3250;

 Dr. Newton E. Kendig, Medical Director, FBOP, nkendig@bop.gov; 

 Eric Holder, Attorney General, Department of Justice, 202-514-2001;

 DOJ public comment line, 202-353-1555, or AskDOJ@usdoj.gov; 

 Office of General Counsel, Kathleen M. Kenny, 202-307-3062;

 The White House, 202-456-1414; and www.bop.gov/inmates/concerns.jsp.

 Select Butner FMC and #99974-555; 

 Thank you.

 Karima Al-Amin for The Imam Jamil Action Network

 www.imamjamilactionnetwork.org